Dr. Arvind Kumar Bansal is a Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab, India. With a career spanning over three decades, he is a globally recognized leader in pharmaceutical research and development, renowned for bridging academic innovation with industrial application.

Dr. Bansal earned his M.Pharm. in Pharmaceutics (1988) and Ph.D. (1993) from the University of Delhi, India. Before joining NIPER in 2000, he honed his expertise as a Senior Scientist and Group Leader at JK Pharmaceuticals and Ranbaxy Research Laboratories for eight years. There, he spearheaded the conceptualization, formulation strategy, and technology transfer of novel chemical entities (NCEs) and generic drug products, laying the groundwork for his impactful academic career.

At NIPER, Dr. Bansal has pioneered advancements in pre-formulation and formulation development, with expertise in amorphous form stabilization, polymorphism, pseudo-polymorphism, particle engineering, salt form screening, oral bioavailability enhancement, compaction physics, and lyophilization. Guided by his mission to develop \"science-based, industrially viable pharmaceutical technologies,\" his research group collaborates closely with the pharmaceutical industry to translate innovations into commercially viable products.

Dr. Bansal’s contributions have earned him prestigious accolades, including being named the first India-based Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2016. His awards include the AAPS Distinguished Educator and Researcher Award, the Innocentive Award, the Organization of Pharmaceutical Producers of India (OPPI) Award, and the Indian Pharmaceutical Association (IPA)-ACG Scitech Innovation Award 2018 for Best Innovative Development of Solid Dosage Form.

His prolific research output includes over 650 industry-sponsored projects in pharmaceutical material characterization, de-formulation studies, and formulation development. Dr. Bansal holds 11 granted patents, has filed 27 additional patents, and has authored 200 research articles and 27 review articles, with a Google Scholar h-index of 60. He serves on the editorial boards of RSC Pharmaceutics, Journal of Excipients and Food Chemicals, Drug Development Research, and Pharmaceutics, and advises the editorial boards of Journal of Pharmaceutical Sciences and Molecular Pharmaceutics.

Dr. Bansal’s leadership extends beyond research, fostering strong academia-industry partnerships and mentoring the next generation of pharmaceutical scientists. His visionary work continues to shape the future of drug development, making significant contributions to global healthcare.

Matthias G. Wacker is Professor of Biopharmaceutics in the Drug Delivery and Disposition Lab at KU Leuven. He received his Ph.D. in Pharmaceutical Technology from Goethe University Frankfurt and completed his habilitation under Prof. Jennifer Dressman and Prof. Jörg Kreuter.
Prior to joining KU Leuven, he led translational formulation research at the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) and served as Associate Professor at the National University of Singapore, where he established an internationally recognized program in biopharmaceutics and complex drug delivery systems.
His research focuses on biopredictive in vitro testing, IVIVC, and the mechanistic transformation of complex dispersed dosage forms, including liposomes, lipid nanoparticles, and long-acting injectables, under physiologically relevant conditions. Prof. Wacker actively contributes to international standardization through USP and ISO committees and serves on several editorial boards. His work has been recognized with multiple awards, and he has been listed among the World’s Top 2% of Scientists since 2022.

Vikram Shukla is a seasoned pharmaceutical professional with over 30 years of distinguished experience in world-class formulation development and manufacturing. Known for his unwavering integrity, strategic foresight, and transformative leadership, Vikram has consistently driven operational excellence across global pharmaceutical landscapes.

He has played pivotal roles in leading manufacturing and quality units, with a strong track record in navigating complex regulatory audits and successfully resolving warning letter challenges. His expertise spans compliance with international regulatory standards, including USFDA, EMA, MHRA, and WHO.

Vikram has held leadership positions at several leading multinational organizations, including Pfizer Inc., Dr. Reddy’s Laboratories, Fresenius Kabi, Lupin, and Zydus Lifesciences, where he currently serves as President of the Injectable vertical. In this role, he oversees end-to-end operations and quality functions, championing innovation and excellence across the business unit.

His technical portfolio encompasses a wide range of dosage forms, including injectables (SVP, LVP, lyophilized, dry powder), sterile APIs, and solid orals. He is also deeply committed to fostering quality-centric cultures, optimizing manufacturing processes, and delivering impactful training in GMP compliance, microbiology, cleanroom practices, and validation methodologies.

An alumnus of INSEAD France, Vikram holds a postgraduate degree in Microbiology from Bombay University (1995) and is a Gold Medallist graduate from Nagpur University (1993).

Dr. Govind S. Pandey is Director of Gamp Technologies Private Limited. He has over three decades of experience in the pharmaceutical industry. He is a professional experienced in sterile operations, solid oral dosage forms, semi solid dosage forms and API. He possesses a deep understanding of business strategy relating to Operations, Quality Assurance, Quality
control, CMC submissions, Facility design, Tech transfer& Regulatory guidelines. In addition, he is black belt certified person on “Six Sigma- Process optimization and Problem solving”. He has provided expert scientific support for the timely resolution of issues raised by USFDA & other Regulatory agencies.

He has held several positions including Chief Operating Officer and Board of Director - Sentiss Pharma Pvt. Ltd., Sr. Vice President - Operations head, responsible for all formulation sites of Wockhardt, Sr. Vice President -Responsible for Intas Pharma sites operations including API, Director - Ranbaxy Labs ltd Mohali, Vice president - Operations head, responsible for Mylan Nashik Site, Vice president - Operations head, responsible for Alkem Baddi site.

He is Six sigma black belt certified on ‘Process Optimisation and Problem Solving’ and an Expert on Computer system Validation and GAMP 5 guideline as well as data integrity assessments in Quality Control laboratories. He has sound knowledge of HVAC and Water system and is good in Engineering, Facility design and Validations.

Mukesh is one of the founder directors of Ortiv-Q3 (A Sotax joint venture), a pioneering pharmaceutical research and testing organization well acknowledged globally for its specialized skill set in IVRT, Q2/Q3 characterization and complex parenterals formulation development. He is a pharmaceutical veteran with over 30 years of industrial experience. He earned his M Pharm (Pharmaceutics) from Jamia Hamdard, New Delhi in (1992) and Ph.D. (2021) from BAMU, Aurangabad. His expertise includes Niche steriles, Value added generics, Topicals and NCEs. He holds 18+ US/EU Patents/Application to his credit and is specially versed in nanotechnology-based platforms including Nanoemulsions, Nanosuspensions, Liposomes, Microspheres, Insitu forming depots and associated Q2/Q3 characterization. He has profound knowledge in formulation development, Quality & compliance, preclinical evaluation, process development, optimisation, and scale-up of formulations for regulated markets. In his past assignments he was associated with many reputed companies like Ranbaxy, Dabur Pharma, Fresenius Kabi, Emcure, Wockhardt and Claris in Sr positions like, Asst. Director, AVP & Technical head (R&D).  He is co-inventor of the innovative microdialysis based IVRT technology developed by Ortiv-Q3 which has been successfully commercialized globally (Indian patent granted, US patent applied). He is also the co-inventor of indigenously developed patented nanoparticle technology for Polymeric micellar delivery of Paclitaxel (NanoxelTM - Fresenius Kabi) that reached from bench scale to the market.  He contributed in many products approvals for various markets including US, EU in his past career. He has also been ranked as the top 2% most-cited scientists in a list published by Stanford University (2021).

Dr. Avijit Kelkar is the Co-founder of Aharav Consultants and creator of the flagship product "HORIZONS" established in May 2018. As a renowned Product, Portfolio, and IP strategist, he brings executive-level experience from top generic pharmaceutical companies, including Dr. Reddy's and Sun Pharma, where he previously headed Portfolio Strategy and IP. Dr. Kelkar provides a broad range of technical expertise essential for strategic risk mitigation and product success, specializing in:

Product Selection and Strategic Risk Assessment
Bioequivalence in Drug Development
Patent Strategy and Litigation Support (including drafting, invalidation, and Trademark actions)

He holds a Post-Doctorate in Organic Chemistry, is a certified European Patent Practitioner, and possesses specialized expertise as a GDPR Consultant within the pharmaceutical sector

Jatin Gajjar is the President of QuoSolve – Pharmaceutical Consultants, advising global pharmaceutical companies on R&D strategy, formulation and analytical troubleshooting, regulatory readiness, and quality-focused development. With 34+ years of experience across leading generic organizations—including Aurobindo, Par/Endo, Amneal, Sun Pharma, and Sanofi—he has contributed to 250+ ANDA/eCTD submissions and supported numerous PAIs, scale-ups, and technology transfers. A Gujarat University topper and gold-medallist, Jatin specializes in complex drug-delivery systems spanning oral solids, transdermal, inhalation products, injectables, and LAIs. He also mentors scientists and serves on the Academic and Research Advisory Councils of L.M. College of Pharmacy. Jatin is empanelled as an expert consultant with BCG and is recognized for helping organizations elevate scientific rigor, reduce development risk, and deliver high-quality generic medicines.

Dr. Sanju Dhawan serves as the Director of Research & Development at Baxter Pharmaceuticals India, where she leads end-to-end pharmaceutical R&D with a focus on formulation science, analytical development, technology transfer, and regulatory-driven innovation. With more than 26 years of extensive industry experience, she has held senior scientific and leadership roles at several prominent organizations, including Pfizer, Cadila Healthcare, Dr. Reddy’s Laboratories, and Panacea Biotec.
Her work spans a wide spectrum of complex product development—ranging from injectables and sterile formulations to advanced drug delivery systems. Dr. Dhawan has contributed to numerous successful product launches and global submissions, supported by her strong expertise in quality systems, problem-solving approaches, and multidisciplinary team leadership.
A prolific contributor to pharmaceutical science, she holds multiple patents, has authored several research publications, and is widely recognized for her commitment to scientific rigor and innovation. At Baxter, she continues to lead strategic R&D initiatives that strengthen the company’s innovation pipeline and support the development of high-quality, patient-centric healthcare solutions.

Dr. Satish Naik is a Principal Scientist at Delpharm Development, Leiden, Netherlands, with over two decades of experience spanning analytical development, CMC strategy, and regulatory science for complex pharmaceutical products. He has extensive expertise in the characterization and development of complex injectables, including liposomes, nanosuspensions, polymer-based depots, peptides, and biologics, supporting products across development and commercialization stages.
Dr. Naik has held senior scientific and analytical leadership roles at Delpharm, Dr. Reddy’s Laboratories (Netherlands and India), Cipla R&D, and served as a CMC Fellow at the U.S. Food and Drug Administration (FDA), where he contributed to advanced characterization strategies for liposomal drug products. His work aligns closely with global regulatory expectations from FDA, EMA, ICH, and other agencies.
He holds a Ph.D. in Chemistry from Goa University and an M.Sc. from Karnatak University, and has authored multiple high-impact scientific publications. His professional focus includes QbD-driven analytics, advanced physicochemical characterization, and regulatory-ready CMC documentation for complex injectable products.

Dr. Deepak Murpani is a senior pharmaceutical R&D leader with over 30 years of experience in the generic pharma industry and 15 years at VP and C-level roles in EU and US based companies. He is currently one of the key stake holders in Andersen Pharma Global LLC, an Australia based company.  He has led global R&D organizations of more than 500 scientists, delivered over 350+ products to US and EU markets, and driven innovation across complex drug delivery technologies. His expertise spans R&D strategy, portfolio optimization, and value-based leadership in regulated markets.

A seasoned pharmaceutical leader with over 34 years of industry experience, including significant exposure to the US generics market, he has progressed from formulation development scientist to senior executive roles including R&D Head, Chief Scientific Officer, and Chief Operating Officer. He has led end-to-end research, manufacturing, quality, regulatory, and business operations, contributing to the development and launch of 300+ products across global markets, including first-to-file generics and exclusivity products. His career spans leading organizations such as Ranbaxy, Sun Pharma, Jubilant, Mylan, Aurobindo, Wockhardt, and he is currently associated with Shilpa Medicare as COO.

Hari Raghuram Desu, Ph.D. holds a Master’s degree (1999) in Pharmaceutics from the National Institute of Pharmaceutical Education and Research (NIPER, Chandigarh) and Doctorate degree (2009) in Pharmaceutics from the University of Tennessee, Memphis, USA. Dr. Hari has held various positions in pharmaceutical companies – Aizant Drug Research Solutions (India), Dr. Reddy’s Research Laboratories (India), InnoPharma (acquired by Pfizer, USA), and Schering-Plough Center for Sterile Products (affiliated with University of Tennessee Health Science Center, Memphis, USA). Currently, Dr. Hari is Director and Head of Research, Complex Products at Aizant Drug Research Solutons. His specific interests include drug delivery, optimization of product compositions with focus on peptides, proteins and nucleic acids, characterization of chemical moieties in solid and liquid states, drug-device combinations, simulation and modelling approaches for optimization of pharmaceutical dosage forms. He has contributed to international peer-reviewed journals, book chapters and is a co-assigneee of patents and patent applications. He has been presenting at international research conferenes such as American Association of Pharmaceutical Sciences (AAPS) and Controlled Release Society (CRS) for several years. 

Dr. Arani Chatterjee is currently President (CRO) at Cadila Pharmaceuticals, which is one of the oldest and the largest privately held pharmaceutical company of India. In this role, Dr. Chatterjee is responsible for Pre-Clinical and Clinical Research including BA/BE studies, bioanalytical assays and clinical trials. He also oversees Pharmacovigilance at Cadila Pharmaceuticals.
Prior to joining Cadila pharmaceuticals, he served at Aurobindo Pharma, Biological E, Panacea Biotec and Dr. Reddy’s Research Foundation since 1998. During his tenure he made significant contributions to the clinical development of New Chemical Entities, vaccines, novel drug delivery products, complex generics and biologics.
Dr. Arani Chatterjee earned his medical degree from Christian Medical College, Vellore and postgraduate degree from National Institute of Mental Health and Neuro Sciences, Bangalore, India. He is also an alumnus of Indian Institute of Management, Indore, India.
He has served as a WHO Adviser for the Global Polio Eradication Initiative and was a member of the drafting group for WHO Guidelines on clinical evaluation of vaccines: regulatory expectations. He was a member of several Brighton Collaboration groups for vaccine safety. He has participated in WHO Strategic Advisory Group of Experts on Immunization and Global Vaccine Safety Initiative meetings, Asia Pacific Dengue Prevention Board Meeting under the Pediatric Dengue Vaccine Initiative of International Vaccine Institute and Pneumococcal Vaccines meetings at UNICEF. He has also participated in in-person pre-IND meetings with USFDA, scientific advice meetings with BfArM (Germany), ANVISA (Brazil), Medsafe (New Zealand), ALIMS (Serbia) and NORCB (Egypt) as well as expert group meetings on Indian GCP guidelines and National Technology Advisory Group on Immunisation meetings.
Dr. Chatterjee serves as a reviewer for the journal ‘Vaccine’ and has 24 peer-reviewed international research publications and 4 book chapters to his credit. He was awarded the prestigious 2012 Charles C. Shepard Award from CDC, Atlanta in 2012.

Dr. Sujoy Mukherjee is an accomplished scientist working at the forefront of complex injectable drug product development, specializing in advanced formulation design, analytical method development and characterization of complex injectables. He is part of a multidisciplinary team of formulation, container closure, and analytical scientists pioneering complex injectable products, including peptide and iron formulations. His team leverages extensive capabilities in both conventional and advanced characterization techniques to support drug development across regulatory markets. Their work focuses on establishing equivalence with reference listed drugs as well as developing differentiated products beyond existing generics through innovative formulation and analytical strategies. In his prior role, he has contributed to the R&D of several approved and commercialized peptide injectables like the glucagon, ganirelix, and liraglutide (Victoza) generic drug products in the US and other countries. Currently, he’s leading the Complex Product Development team at Baxter Pharmaceuticals India Pvt. Ltd.
Dr. Mukherjee brings strong proficiency in advanced chromatographic, spectroscopic, and light-scattering techniques, complemented by biological assays and immunological risk assessment, enabling robust evaluation of complex drug products. Multifaceted innovation has been central to his contributions in developing both generic and differentiated products for diverse regulatory pathways.
In his previous role in academia, he worked in the area of structural and molecular biology and made meaningful contributions to understanding protein dynamics and their implications for human health. His expertise spans upstream, downstream, and analytical characterization, employing advanced NMR, spectroscopic and computational approaches to elucidate biomolecular structures, interactions, and mechanisms relevant to disease understanding and therapeutic development. He has a B.Tech in Biotechnology & Biochemical Engineering from IIT Kharagpur and PhD in Biophysics & Computational Biology from the University of Illinois, Urbana-Champaign.

Dr. Mayur Sankalia is currently serving as the Vice President of Research & Development at Invengene Pvt Ltd, bringing over 25 years of expertise in pharmaceutical product development, spanning conventional and specialty dosage forms. Dr. Sankalia obtained his Bachelor's degree in Pharmacy from Sardar Patel University and went on to complete his Master’s and PhD in Pharmaceutical Sciences from The Maharaja Sayajirao University (MSU) of Baroda. His doctoral research commenced while he was a lecturer at MSU, later transitioning into a full-time Senior Research Fellow under the University Grants Commission (UGC) fellowship.
Post-PhD, he joined Sun Pharma Advanced Research Centre, where he played a pivotal role in the development of complex generic products and contributed to an innovative drug- complex conjugate, securing a world patent in his name. In 2009, he moved to the UK as a Postdoctoral Research Fellow at Queen’s University Belfast, focusing on topical hydrogel stability enhancement. He then joined Norbrook Pharmaceuticals, a global leader in veterinary and animal health medicines, contributing to novel formulation development. 
Returning to India in 2011, Dr. Sankalia joined Mylan Laboratories Limited, leading the development of NDDS-based complex generic dosage forms, including oncological and non- oncological injectables, lyophilized formulations, dry powders, ophthalmic formulations, and more. In 2015, he transitioned to Dr. Reddy’s Laboratories, filing multiple products and facilitating technology transfer between the Netherlands and India for liposomal injectables. Subsequently, as Head of R&D at Celon Laboratories, he commercialized complex products such as peptide microspheres, albumin-bound nanoparticles, and oncology formulations. 
Currently, at Invengene, Dr. Sankalia is spearheading the establishment of the injectable product development, overseeing R&D operations, regulatory affairs, and seamless technology transfer. His strategic leadership has led to multiple global regulatory approvals and successful commercialization of several formulations. Dr. Sankalia has authored 24 publications in peer-reviewed journals and holds three granted patents. Originally from Saurashtra, Gujarat, he is married to Dr. Jolly Sankalia and is a proud father of two daughters. In his leisure time, he enjoys reading, traveling, and photography.

Dr. Nitish Sharma is an accomplished pharmaceutical analyst and academician with nearly 15 years of extensive experience spanning the pharmaceutical industry and academia. He is currently serving as Assistant Professor in the Department of Pharmaceutical Analysis at the National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, an Institute of National Importance under the Government of India, where he has been contributing since April 2021
Dr. Sharma holds a Ph.D. in Chemistry from JNT University, Hyderabad, and an M.Sc. in Organic Chemistry from Jiwaji University, Gwalior. Prior to joining NIPER, he held key leadership and research roles at Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd., where he specialized in analytical research and development for APIs, synthetic peptides, complex injectables, and regulated markets (US–EU) 
His core expertise includes analytical method development and validation, impurity profiling, nitrosamine and genotoxic impurity assessment, extractables and leachables studies, HRMS-based characterization, particle size and nano-suspension analysis, and reverse engineering of reference listed products. He has also been actively involved in pre-formulation analytics, impurity isolation, and technical transfer of analytical methods to quality control environments 
Dr. Sharma is internationally engaged in pharmacopeial and regulatory science. He is a Member of the Nominating Committee for the Council of Experts at the United States Pharmacopeia (USP) and has participated in the USP Convention in the USA. He is also a Member of the Chromatographic Separation Techniques Working Party of the European Pharmacopoeia and serves as a Technical Assessor with NABL (ISO/IEC 17025) 
A recognized contributor to pharmaceutical research, Dr. Sharma has published approximately 45 research and review articles in international journals and serves as a reviewer/editor for academic journals. His achievements have been acknowledged through several prestigious honors, including the Professor M. L. Khorana Memorial Award (IPA), the ICMR Young Travel Scientist Award, and the Faculty Excellence Award (APT-2025, IIT Bombay) 

Dr. Vaibhav Dubey is currently working as Senior General Manager and leading the Biologic Formulation, Device and Non-Clinical development at Kashiv Biosciences, LLC .  In his previous role, Dr. Vaibhav was General Manager at Alembic Pharmaceuticals where he led various cross-functional teams and initiatives in the areas of new drug/ biologic delivery systems and modalities for both sterile and non-sterile applications. He was also involved in development and commercialization of various ophthalmic and dermatological products. In the other roles, Dr. Dubey worked with Sun Pharma Advanced Research Company Ltd and Dr. Reddy’s Ltd,  wherein he led the team of scientists working on 505 b(1)/ 505 b (2) formulation development approaches alongwith development of multiple generic pharmaceutical products for regulated markets.  Dr. Dubey holds an M.Pharm and PhD degree in drug delivery from Dr. H.S. Gour University. He was also a Commonwealth Scholar at School of Pharmacy, University of London, and recipient of many awards and accolades at prestigious platforms. With numerous well cited publications and technology patents, he is a sought-after Key Opinion Leader in the areas of drug and biologic formulation and device development.